3,4,5,4'-四甲氧基二苯乙烯

生物活性体外研究体内研究 3,4,5,4'-四甲氧基二苯乙烯试剂级价格

3,4,5,4'-四甲氧基二苯乙烯

CAS号:134029-62-2
英文名:3,4,5,4'-TETRAMETHOXYSTILBENE
中文名:3,4,5,4'-四甲氧基二苯乙烯
CBNumber:CB21441938
分子式:C18H20O4
分子量:300.349
MOL File:134029-62-2.mol

3,4,5,4'-四甲氧基二苯乙烯化学性质

熔点 :157-159℃
沸点 :444.0±40.0 °C(Predicted)
密度 :1.117
储存条件 :2-8°C
溶解度 :DMSO: soluble5mg/mL, clear (warmed)
形态 :powder
颜色 :white to beige

安全信息

WGK Germany :3

3,4,5,4'-四甲氧基二苯乙烯性质、用途与生产工艺

生物活性 DMU-212 是一种白藜芦醇 (HY-16561) 甲基化衍生物，具有抗分裂、抗增殖、抗氧化和促进细胞凋亡的活性。DMU-212 通过诱导凋亡 (apoptosis) 和激活 ERK1/2 蛋白导致有丝分裂停止。DMU-212 具有口服活性。

体外研究

DMU-212 (0.3125-40 μM) inhibits growth of A375, MeWo, Bro and M5 cells human melanoma cells.
DMU-212 (30-50 μM; 24 hours) induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells.
DMU-212 induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells.
DMU-212 induces G2/M arrest and apoptosis in cancer cells.
DMU-212 induces mitotic arrest, apoptosis and activation of ERK1/2 protein.

Cell Proliferation Assay

Cell Line:	A375 cells, MeWo cells, M5 cells, Bro cells
Concentration:	0.3125 μM, 0,625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	96 hours
Result:	Inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC ₅₀ =0.5 μM for A375 and Bro and IC ₅₀ = 1.25 μM for MeWo and M5 cells).

Cell Cycle Analysis

Cell Line:	A375 cells
Concentration:	20 μM, 30 μM, 50 μM
Incubation Time:	24 hours
Result:	Caused a marked increase in the levels of p21, p53 and cyclin B1 proteins with a concomitant decrease in the levels of cyclin A2.

Western Blot Analysis

Cell Line:	A375 cells
Concentration:	20 μM, 30 μM, 50 μM
Incubation Time:	24 hours
Result:	Significant upregulation of Bax, caspase 3 and caspase 9 protein levels, while the levels of the anti-apoptotic protein Bcl-2 were decreased.

体内研究

DMU-212 (50 mg/kg; i.g.; three times a week; for 14 days) inhibits tumor growth in xenograft model of human ovarian cancer.

Animal Model:	6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts
Dosage:	50 mg/kg
Administration:	Oral gavage, three times a week, for 14 days
Result:	Lower tumor burden.